These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

701 related items for PubMed ID: 19805519

  • 1. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
    Chen S, Dai Y, Pei XY, Grant S.
    Mol Cell Biol; 2009 Dec; 29(23):6149-69. PubMed ID: 19805519
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
    Huang S, Sinicrope FA.
    Cancer Res; 2008 Apr 15; 68(8):2944-51. PubMed ID: 18413764
    [Abstract] [Full Text] [Related]

  • 6. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
    Pétigny-Lechartier C, Duboc C, Jebahi A, Louis MH, Abeilard E, Denoyelle C, Gauduchon P, Poulain L, Villedieu M.
    Mol Cancer Ther; 2017 Jan 15; 16(1):102-115. PubMed ID: 27980105
    [Abstract] [Full Text] [Related]

  • 7. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
    Rahmani M, Aust MM, Hawkins E, Parker RE, Ross M, Kmieciak M, Reshko LB, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Grant S.
    Haematologica; 2015 Dec 15; 100(12):1553-63. PubMed ID: 26452980
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells.
    Zhang XD, Gillespie SK, Borrow JM, Hersey P.
    Mol Cancer Ther; 2004 Apr 15; 3(4):425-35. PubMed ID: 15078986
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53.
    Zhang J, Huang K, O'Neill KL, Pang X, Luo X.
    Cell Death Dis; 2016 Jun 16; 7(6):e2266. PubMed ID: 27310874
    [Abstract] [Full Text] [Related]

  • 12. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
    Rooswinkel RW, van de Kooij B, Verheij M, Borst J.
    Cell Death Dis; 2012 Aug 09; 3(8):e366. PubMed ID: 22875003
    [Abstract] [Full Text] [Related]

  • 13. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.
    Morales AA, Kurtoglu M, Matulis SM, Liu J, Siefker D, Gutman DM, Kaufman JL, Lee KP, Lonial S, Boise LH.
    Blood; 2011 Aug 04; 118(5):1329-39. PubMed ID: 21659544
    [Abstract] [Full Text] [Related]

  • 14. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
    Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, McQueen T, Bornmann W, Tsao T, Bergamo P, Mak DH, Chen W, McCubrey J, Tafuri A, Andreeff M.
    Leukemia; 2012 Apr 04; 26(4):778-87. PubMed ID: 22064351
    [Abstract] [Full Text] [Related]

  • 15. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner.
    Kazi A, Sun J, Doi K, Sung SS, Takahashi Y, Yin H, Rodriguez JM, Becerril J, Berndt N, Hamilton AD, Wang HG, Sebti SM.
    J Biol Chem; 2011 Mar 18; 286(11):9382-92. PubMed ID: 21148306
    [Abstract] [Full Text] [Related]

  • 16. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
    Nalluri S, Peirce SK, Tanos R, Abdella HA, Karmali D, Hogarty MD, Goldsmith KC.
    Cancer Biol Ther; 2015 Mar 18; 16(2):276-86. PubMed ID: 25756510
    [Abstract] [Full Text] [Related]

  • 17. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
    Hauck P, Chao BH, Litz J, Krystal GW.
    Mol Cancer Ther; 2009 Apr 18; 8(4):883-92. PubMed ID: 19372561
    [Abstract] [Full Text] [Related]

  • 18. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
    Mérino D, Khaw SL, Glaser SP, Anderson DJ, Belmont LD, Wong C, Yue P, Robati M, Phipson B, Fairlie WD, Lee EF, Campbell KJ, Vandenberg CJ, Cory S, Roberts AW, Ludlam MJ, Huang DC, Bouillet P.
    Blood; 2012 Jun 14; 119(24):5807-16. PubMed ID: 22538851
    [Abstract] [Full Text] [Related]

  • 19. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
    Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, Warner RB, Ng SC, Fesik SW, Elmore SW, Rosenberg SH, Tse C.
    Cancer Res; 2007 Feb 01; 67(3):1176-83. PubMed ID: 17283153
    [Abstract] [Full Text] [Related]

  • 20. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K, N'Diaye M, Lheureux S, Loussouarn C, Dutoit S, Briand M, Giffard F, Brotin E, Blanc-Fournier C, Poulain L.
    Apoptosis; 2013 Apr 01; 18(4):492-508. PubMed ID: 23344663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.